Results 251 to 260 of about 158,759 (293)

Coronary Heart Disease Patients' Knowledge, Attitudes, and Practices Regarding Coronary Artery Bypass Grafting. [PDF]

Patient Prefer Adherence
Dong W, Yang B, Li X, Zhang R, Chen Q, Peng W, Li Z, Zeng F, Li T, Zhu S.   +9 more
europepmc   +1 more source

Effects of early mobilization on patients after coronary artery bypass grafting: a Meta-analysis [PDF]

Xiaoxia Hao, Mengge Li, Sijia Li, Yang Xiuchun, Yijun Zong   +4 more
openalex   +1 more source

Equine experimental lameness induction models

Equine Veterinary Education, EarlyView.
Summary Equine lameness due to musculoskeletal injury remains a common and significant cause of decreased performance. While our understanding and management of lameness have improved with advanced imaging, as well as diagnostic and therapeutic progression, a need for experimental equine models of lameness remains.
A. Dockery, B. Beasley, V. J. Moorman
wiley   +1 more source

Preoperative Guidelines for Coronary Artery Bypass Grafting for Health Education and Anxiety Management: Scoping Review. [PDF]

Scientifica (Cairo)
de Araújo NM, Silva SO, da Silva BVS, Cabral MAL, da Fonseca JF, Camara RPPOA, da Silva MCB, Dantas RAN, Dantas DV.   +8 more
europepmc   +1 more source

Leadless Versus Transvenous Dual‐Chamber Pacemakers: Real‐World Evidence From AVEIR DR Coverage With Evidence Development Study

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background AVEIR DR, an industry‐first dual‐chamber leadless pacemaker (LP), provides continuous atrioventricular synchrony through implant‐to‐implant (i2i) communication between atrial and ventricular LP devices. It is important to evaluate the early real‐world comparative safety of AVEIR DR LP.
Monica Lo, Anish K. Amin, Marcin Kowalski, Anne Kroman, Dilip Mathew, Valay Parikh, Stanislav Weiner, Jennifer M. Joseph, Leonard Ganz, Mohammed Mortada, AVEIR DR Study Group/Consortium   +10 more
wiley   +1 more source

National Variation in the Use of Multiple Arterial Grafting in Isolated Coronary Artery Bypass Grafting in the United Kingdom. [PDF]

Eur J Cardiothorac Surg
Chan J, Comanici M, Dong T, Narayan P, Fudulu DP, Angelini GD, Angelini GD.   +6 more
europepmc   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Dias Gabriela, Paraskevi Xepapadak, Dangi Priyanshi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Hamed Nasr Iman, Al Hinai Bushra, Joanna Bartosińska, Dorota Krasowska, Szczepanik‐Kułak Paulina, Gungor Hilal, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado   +33 more
wiley   +1 more source

Rare Intraoperative Left Coronary Artery Dissection in Acute Type A Aortic Dissection: VA-ECMO-Assisted Coronary Artery Bypass Grafting. [PDF]

Clin Case Rep
Nakamura Y, Saku K, Homma S, Moriyama N, Ota T.   +4 more
europepmc   +1 more source

Coronary Artery Bypass Grafting: 30-Day Operative Morbidity Analysis in 1046 Patients

, 2012
AlWaqfi
openalex   +2 more sources

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source